Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course Tislelizumab Adjuvant Therapy in Stage II dMMR/MSI-H Colorectal Cancer
NCT06520683Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2024
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of tislelizumab in colorectal cancer (CRC), sponsored by Sun Yat-sen University. Started Nov 2024; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06520683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06520683.